Back to the future: Inhaled drug products

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1165-1172

  Hickey, Anthony J ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Aerosols; Biotechnology; Drug delivery systems; Inhaled dosage forms; Peptides and proteins; Pulmonary

Indexed keywords

ADVASURE; AERX INHALED INSULIN; AIR INSULIN; ARD 1100; ARD 3100; ARD 3150; ARFORMOTEROL; AZTREONAM LYSINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CIPROFLOXACIN; DIHYDROERGOTAMINE MESILATE; DORNASE ALFA; FLUNISOLIDE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; GAMMA INTERFERON; GENERIC DRUG; ILOPROST; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LEVALBUTEROL; LOXAPINE; MANNITOL; MOMETASONE FUROATE; PROPELLANT; RECOMBINANT HUMAN INSULIN; SALBUTAMOL SULFATE; STACCATO; TIOTROPIUM BROMIDE; TOBRAMYCIN; TREPROSTINIL; TYVASCO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROSOL; ARTICLE; ASTHMA; ATYPICAL MYCOBACTERIOSIS; BIPOLAR DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; FIBROSING ALVEOLITIS; GOVERNMENT REGULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICAL NEBULIZER; METERED DOSE INHALER; MIGRAINE; POWDER INHALER; PRESSURE; PSEUDOMONAS INFECTION; PULMONARY HYPERTENSION; SCHIZOPHRENIA; SOFT MIST SPRAY;

EID: 84874709963     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23465     Document Type: Article

References (52)

1. Thiel CG. 1996. From Susie's question to CFC free: An inventor's perspective on forty years of MDI development and regulation. In Proceedings of Respiratory Drug Delivery V; Dalby RN, Byron PR, Farr SJ, Eds. Raleigh, North Carolina: Serentec Press, pp 115-124.
2. Purewal TS, Grant DJW, Eds. 1998. Metered dose inhaler technology. Buffalo Grove, Illinois: Interpharm Press.
3. Hickey AJ, Ed. 2004. Summary of common approaches to pharmaceutical aerosol administration. In Pharmaceutical inhalation aerosol technology. Hickey AJ, Ed. 2nd ed. New York: Marcel Dekker, pp 385-421.
4. Sanders M. 2011. Pulmonary drug delivery: an historical overview. In Controlled pulmonary drug delivery. Smyth HDC, Hickey AJ, Eds. New York: Springer, pp 51-73.
5. Olivieri D, Barnes PJ, Hurd SS, Folco GC, Eds. 1992. Asthma treatment: A multidisciplinary approach; NATO ASI Series. New York: Plenum.
6. Ganderton D, Jones T. 1987. Drug delivery to the respiratory tract; Ellis Horwood series in biomedicine. New York: VCH, Ellis Horwood.
7. Lötvall J. 2001. Inhalation therapy of the future-How will it change the way we treat asthma? J Aerosol Med 14(suppl 1):45-50.
8. Gonda I. 2000. The ascent of pulmonary drug delivery. J Pharm Sci 89:940-945.
9. Cipolla DC, Gonda I. 2011. Formulatio technology to repurpose drugs for inhalation delivery. Drug Discov Today Ther Strateg 8:123-130.
10. Smyth HDC, Garmise R, Cooney D, Garcia-Contreras L, Jones LD, Hickey AJ. 2004. Medical and pharmaceutical aerosols. In Aerosols handbook: Measurement, dosimetry, and health effects. Ruzer L, Harley NH, Eds. Boca Raton, Florida: CRC Press.
11. Clark AR. 2004. Pulmonary delivery technology: Recent advances and potential for the new millenium. In Pharmaceutical inhalation aerosol technology. Hickey AJ, Ed. 2nd ed. New York: Marcel Dekker, pp 571-591.
12. Finlay WA. 2001. The mechanics of inhaled pharmaceutical aerosols, an introduction. New York: Academic Press.
13. Newman SP. 2012. Respiratory drug delivery: Essential theory and practice. Richmond, Virginia: RDD Online.
14. Barnes PJ, Stockley RA. 2004. Current therapeutic interventions and future approaches. Eur Resp J 25:1084-1106.
15. Berger WE. 2008. New approaches to managing asthma: A US perspective. Ther Clin Risk Manag 4:363-379.
16. Hickey AJ. 2005. Pulmonary drug delivery: Pharmaceutical chemistry and aerosol technology. In Drug delivery principles and approaches. Wang B, Siahaan T, and Soltero RA, Eds. New York: Wiley Interscience, pp 341-361.
17. Garcia-Contreras L, Hickey AJ. 2003. Aerosol treatment of cystic fibrosis, Crit Rev Ther Drug Carrier Syst 20:317-356.
18. Billman D, Nicks J, Schumacher R. 1994. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome. Pediatr Pulmonol 18:279-283.
19. Morley CJ. 1984. Surfactant treatment for respiratory distress syndrome, a review. J Roy Soc Med 77:788-792.
20. Gonda I. 2006. Systemic delivery of drugs to humans via inhalation. J Aerosol Med 19:47-53.
21. Gringauz A. 1997. Introduction to medicinal chemistry, how drugs act and why. New York: Wiley-VCH.
22. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. 1994. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 21:77-83.
23. Robinson M, Daviskas E, Eberl S, Baker J, Chan H-K, Anderson SD, Bye PTP. 1999.The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot study. Eur Respir J 14:678-685.
24. Kesser KC, Geller DE. 2009. New aerosol delivery devices for cystic fibrosis. Resp Care 54:754-768.
25. Farr SJ, Taylor G. 1997. Insulin inhalation: Its potential as a nonparenteral method of administration. In Inhalation delivery of therapeutic peptides and proteins. Adjei AL, Gupta PK, Eds. pp 371-387.
26. von Kriegstein E, von Kriegstein K. 2007. Inhaled insulin for diabetes mellitus. NEJM 357:2106-2108.
27. Arnolds S, Heise T. 2007. Inhaled insulin. Best Pract Res Endocrinol Metab 21:555-571
28. Heinemann L. 2008. The failure of Exubera: Are we beating a dead horse? J Diabetes Sci Technol 2:518-529.
29. Siekmeier R, Scheuch G. 2008. Inhaled insulin-Does it become a reality? J Physiol Pharmacol 59(Suppl. 6):81-113.
30. Groves MJ, Alkan MH, Hickey AJ. 1992. The formulation of proteins and peptides. In Pharmaceutical biotechnology, fundamentals and essentials. Klegerman ME and Groves MJ, Eds. Bufffalo Grove, Illinois: Interpharm Press, pp 218-253.
31. Gallo M, Esposito K, Giugliano D. 2012. Diabetes medications and cancer: A way out of uncertainty. Diabetes Res Clin Pract 9::175-177.
32. Lu D, Hickey AJ. 2007. Pulmonary vaccine delivery. Expert RevVacc 6:213-226.
33. Kamada Limited. 2012. International study evaluating the safety and efficacy of inhaled human Alph-1-Antitrypsin (AAT) in Alpha-1 antitrypsin deficient patients with emphysema. NCT01217671, August 2012, Clinical Trials.gov (http://www.clinicaltrials.gov/ct2/results?term=NCT01217671&Search=Search).
34. Heath V. 2009. Pediatrics: Inhaled growth hormone tested in children. Nat Rev Endocrinol 5:417.
35. Diaz KT, Skaria S, Harris K, Solomita M, Lau S, Bauer K, Smaldone GC, Condos R. 2012. Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis. J Aerosol Med Pulmon Drug Deliv 25:79-87.
36. Hallstrand TS, Ochs HD, Zhu Q, Liles W. 2004. Inhaled IFN-gamma for persistent non tuberculous mycobacterial disease due to IFN-gamma deficiency. Eur Respir J 24:367-370.
37. Baker SE, Hockman RH. 2005. Inhaled Iloprost in pulmonary arterial hypertension. Ann Pharmacother 39:1265-1274.
38. Niven RW. 2011. Toward managing chronic rejection after lung transplant. The fate and effects of inhaled cyclosporine in a complex environment. Adv Drug Deliv Rev 63:88-109.
39. Adams WP, Ahrens RC, Chen M-L, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJP, Suarez SS, Suman JD, Weda M, Woodcock J, Yu L. 2010. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): Workshop summary report. JAMPDD 23:1-30.
40. Hickey AJ, Ganderton D. 2010. Quality by design. In Pharmaceutical process engineering. 2nd ed. New York: Informa Healthcare, pp 193-196.
41. Waldrep JC, Dhand R. 2008. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Del 5:114-119.
42. Crowder TM, Louey MD, Sethuraman VV, Smyth HDC, Hickey AJ. 2001. An odyssey in inhaler formulation and design. Pharm Technol 25:99-113.
43. Adams WP, Lee SL, Plourde R, Lionberger RA Jr, Bertha CM, Doub William H, Jean-Marc Bovet, Hickey Anthony J. 2012. Effects of device and formulation on in vitro performance of dry powder inhalers. AAPS J 14:400-409.
44. Hoekman JD, Ho RJY. 2011. Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution, AAPS PharmSci Tech 12:534-543.
45. Maher LE, Woodhouse A, Ward ME, Farr SJ, Rubsamen RA, Etherington LG. 1998. Pulmonary administration of aerosolized fentanyl: Pharmacokinetic analysis of systemic delivery. Br J Clin Pharacol 46:37-43.
46. Craft S. 2012. Insulin resistance and AD-Extending the translational path. Nat Rev Neurol 8:360-362.
47. Hoekman JD, Ho RJY. 2011. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium of rats. Anesth Analg 113:641-651.
48. Strittmatter WJ. 2012. Altzheimer's disease: The new promise. J Clin Invest 122:1191.
49. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. 2012. Intranasal insulin therapy for Altzheimer disease and amnestic mild cognitive disorder. Arch Neurol 69:29-38.
50. Frauman AG, Cooper ME, Parsons BJ, Jerums G, Louis WJ. 1987. Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care 10:573-578.
51. U.S. Department of Health and Human Services, Food and Drug Administration (http://www.fda.gov/newsevents/publichealthfocus/ucm172906.htm, October 9th 2010).
52. Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N. 2007. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177-3187.